EB-1020

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Efficacy and SafetyAdult

242 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

1

Rilutek

AAzurity Pharmaceuticals

Phase 3

32

Glypressin

MMallinckrodt

Phase 3

13

DWP16001

Daewoong Pharmaceutical Co. LTD.

Phase 3

14

Becotatug Vedotin

FFudan University

Phase 3

15

S1,

CChinese Academy of Medical Sciences

Phase 3

16

Esketamine Hydrochloride

TThe Second Hospital of Anhui Medical University

Phase 3

17

Cyclosporin a

Novartis

Phase 3

18

NVX-Cov2705

Sanofi

Phase 3

19

Sodium Oligomannate

GGreen Valley (Shanghai) Pharmaceuticals Co., Ltd.

Phase 3

210

EB-1020

Otsuka

Phase 3

1Show 37 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Efficacy and Safety1 trial

Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients

Recruiting·Otsuka·Phase 2/3·NCT06931080·630 enrolled

Adult1 trial

A Long-term Trial of EB-1020 in Adult Patients With ADHD

Recruiting·Otsuka·Phase 3·NCT06926829·180 enrolled

Tolerance1 trial

A Study to Evaluate the Safety, Tolerance, and Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020

Completed·NNeurovance, Inc.·Phase 1·NCT01744808·54 enrolled

Abuse Potential1 trial

A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users

Completed·NNeurovance, Inc.·Phase 1·NCT02144415·80 enrolled

Details

Drug Info

Related News